Clinical trials: Sickle Cell Crisis
Sickle Cell Anemia Crisis
Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Patients With Acute Sickle Cell Crises?
The purpose of this study is to determine whether IV acetaminophen can decrease the need for subsequent opioid administration in the acute management of sickle cell crisis pain in the pediatric emergency room.
- Trial name
- NCT03541980
- Testing
- Acetaminophen, Normal saline
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Newark Beth Israel Medical Center
Vaso-occlusive Crisis
Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric
Sickle cell disease (SCD) is characterized by an abnormal hemoglobin, the main protein in the red blood cell. From the first months of life, acute obstruction of the vessels of the microcirculation manifests as intense and…
- Trial name
- INVOPE (NCT06181695)
- Testing
- Sufentanil
- Volunteers
- 182 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Anemia, Sickle Cell, Anemia; Sickle-Cell, With Crisis
Hydroxyurea in the Emergency Room to Lessen Pain in Sickle Cell Crisis
This study will investigate the safety, tolerability and potential for the use of up to three daily doses of 30-40 mg/kg HU (daily) upon hospitalization for painful vaso-occlusive crises .
- Trial name
- HELPS (NCT03062501)
- Testing
- Hydroxyurea
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti
Vaso-occlusive Crisis, Sickle Cell Disease
Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia
The aim of the present study is comparing the effectiveness of different treatment regimens for investigating the therapeutic potential for each one in management of Vaso-occlusive pain in pediatric sickle cell disease.
- Conditions
- Vaso-occlusive Crisis, Sickle Cell Disease, Sickle Cell Anemia in Children
- Trial name
- NCT04301336
- Testing
- Omega 3, Vit D, Zinc sulfate
- Where
- 4 sites in Egypt, Saudi Arabia
- Volunteers
- 350 people
- Sponsor
- Beni-Suef University
Sickle Cell Disease Vaso-occlusive Crisis
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
This is a phase 2, randomized, multiple-dose, placebo-controlled study designed to evaluate the safety, efficacy, and pharmacokinetics (PK) of CSL889 (human hemopexin) when given intravenously (IV) to adults and adolescents with…
- Trial name
- NCT06699849
- Testing
- CSL889
- Where
- 30 sites in United States, Turkey (Türkiye) and 1 more
- Volunteers
- 70 people
- Sponsor
- CSL Behring
Other Sickle-cell Disorders With Crisis, Unspecified
Quality of Life Study for Sickle Cell Patients Treated With Jobelyn (Sorghum Bicolor Extract)
The purpose of this study is to determine the antioxidant effect of prolonged use of sorghum bicolor (jobelyn) to increase the level of plasma superoxide dismutase and glutathione reductase in patients with sickle cell disease…
- Trial name
- NCT01704794
- Testing
- Folic Acid + Paludrine + Jobelyn (500mg), Folic Acid + Paludrine + Jobelyn (250mg), Folic Acid + Paludrine + Jobelyn (2mg)
- Where
- Nigeria
- Volunteers
- 96 people
- Sponsor
- Lagos State University
Sickle Cell Disease
Blood Flow and Pain Crises in People With Sickle Cell Disease
Background: Many people with sickle cell disease have repeated episodes of severe pain that lasts for days, requiring hospital care. These episodes, called pain crises, may be caused by changes in blood flow.
- Trial name
- NCT01568710
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pain, Sickle Cell Disorder
Ketamine Infusion for Acute Sickle Cell Crisis in the Emergency Department
Pain associated with sickle cell disease is a common emergency department visit. It is also frequently associated with a high emergency department recidivism rate for pain control and admissions to the hospital.
- Trial name
- KISS (NCT02417298)
- Testing
- Normal saline, Ketamine
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Billy Sin
SCD, Vaso Occlussive Crisis
Efficacy of Liberal Versus Restricted IV Fluid Approach in the Management of Sickle Cell Vaso-Occlusive Crisis
Sickle cell disease (SCD) is a prevalent inherited blood disorder characterized by vaso-occlusive crises (VOCs), which lead to severe pain and complications.
- Trial name
- FLASC (NCT07188766)
- Testing
- Sodium Chloride (NaCl) 0.9 %
- Where
- 2 sites in Saudi Arabia
- Volunteers
- 394 people
- Sponsor
- Imam Abdulrahman Bin Faisal University
Sickle Cell Disease, Sickle Cell Anemia
Microvascular Blood Flow in Sickle Cell Anemia
Sickle cell disease (SCD) is an inherited blood disorder that causes the red blood cells to change their shape from a round shape to a half-moon/crescent or sickled shape.
- Trial name
- NCT01566890
- Testing
- regadenoson infusion with contrast-enhanced ultrasound, contrast-enhanced ultrasound
- Where
- 2 sites in United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Versiti Blood Health
Sickle Cell Crisis
Sickle Cell Improvement: Enhancing Care in the Emergency Department
Sickle cell disease (SCD) is an inherited blood disorder affecting approximately 36,000 children in the United States, approximately 90% of whom are Black.
- Trial name
- SCIENCE (NCT05373771)
- Testing
- Care pathway
- Where
- United States
- Volunteers
- 5,328 people
- Sponsor
- Medical College of Wisconsin
Sickle Cell Disease, Sickle Cell Crisis
Ketorolac for Acute Vaso-Occlusive Crisis in Pediatric Sickle Cell Disease
Pediatric patients who present with acute vaso-occlusive pain crisis may have equivalent pain reduction scores at lower dosing of intravenous Ketorolac compared to standard dosing of 0.5 mg/kg/dose IV (<16yo max 15mg, >16yo max…
- Conditions
- Sickle Cell Disease, Sickle Cell Crisis, Veno-occlusive Disease
- Trial name
- NCT06579703
- Testing
- Ketorolac
- Volunteers
- 102 people
- Sponsor
- Children's Blood and Cancer Center at Dell Children's Medical Center
Sickle Cell Crisis, Sickle Cell Disease
Mindfulness and Yoga Therapy for Acute Pain in Sickle Cell Disease
Patients with sickle cell disease suffer from acute and chronic pain that diminishes their quality of life. The purpose of this study is to assess the feasibility and acceptability of mindfulness meditation, breathing exercises…
- Trial name
- NCT05572294
- Testing
- Mindfulness meditation, breathing exercises (including incentive spirometry), and yoga therapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Texas Southwestern Medical Center
Sickle Cell Anemia, Sickle Cell Thalassemia
Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease
Background: Sickle cell disease (SCD) is an inherited blood disorder. The disease affects the ability of red blood cells to carry oxygen; this in turn can injure organs including the heart, lungs, and kidneys.
- Conditions
- Sickle Cell Anemia, Sickle Cell Thalassemia, Sickle Cell Pain, Hbss
- Trial name
- NCT05675436
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Sickle Cell Disease
Prevention of Vaso-occlusive Painful Crisis by Using Omega-3 Fatty Acid Supplements
140 SCD patients [70 on Hydroxyurea] will receive Omega-3 capsules whereas another 140 SCD patients [70 on Hydroxyurea] will receive placebo and will be recruited from the Sultan Qaboos University Hospital [SQUH] haematology…
- Trial name
- OM3FA (NCT02525107)
- Testing
- Omega-3 capsules
- Where
- Oman
- Volunteers
- 280 people
- Sponsor
- Sultan Qaboos University
Sickle Cell Disease
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
This is a phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study investigating the safety of anumigilimab administered subcutaneously (SC) at the maximum tolerated dose (MTD) in adult participants with…
- Trial name
- NCT07224360
- Testing
- Anumigilimab
- Where
- 38 sites in United States, Belgium and 5 more
- Volunteers
- 63 people
- Sponsor
- CSL Behring
Sickle Cell Disease, Vaso-occlusive Crisis
Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis
GMI-1070 is a new drug that may reduce the stickiness of cells in the blood. The purpose of this study is to evaluate whether GMI-1070 can reduce the time it takes for pain to go away in patients with vaso-occlusive crisis (also…
- Conditions
- Sickle Cell Disease, Vaso-occlusive Crisis, Pain Crisis
- Trial name
- NCT01119833
- Testing
- GMI-1070
- Where
- 22 sites in United States, Canada
- Volunteers
- 81 people
- Sponsor
- GlycoMimetics Incorporated
Sickle Cell Disease (SCD), Vaso-occlusive Events
Standard of Care Comparative Arm of Phase 1/2 Gene Therapy Trial DREPAMIR" in Severe Sickle Cell Disease Patients
The purpose of this study is to compare the efficacy and safety of transplantation of gene modified autologous CD34+ cells in SCD patients within a therapeutic strategy that may include anti-inflammatory treatment as a…
- Trial name
- Drepamir-soc (NCT07752043)
- Testing
- standard of care
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Sickle-Cell Disease with Crisis
Analgesic Effect of Parecoxib Versus Morphine in SCD Patients Presenting to the Emergency Department
Introduction: This study focuses on the treatment of painful crises in Sickle Cell Disease (SCD) patients using Paracoxib, a non-opioid, compared to Morphine.
- Trial name
- PASC (NCT06315920)
- Testing
- Parecoxib, Morphine
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- Oman Medical Speciality Board
Sickle Cell Disease
High-flow Oxygen for Vaso-occlusive Pain Crisis
Sickle cell disease (SCD) is characterized by recurrent vaso-occlusive pain crisis (VOC), which may evolve to acute chest syndrome (ACS), the most common cause of death among adult patients with SCD.
- Trial name
- OSONE (NCT03976180)
- Testing
- Stadard low-flow oxygen, HFNO with low FiO2 (21%-30%), HFNO with intermediate FiO2 (50%)
- Where
- France
- Volunteers
- 350 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris